Liquidia shares sink nearly 50% after Delaware federal court finds Yutrepia infringed United Therapeutics patent claims
AI Market Summary
A US District Court in Delaware ruled Liquidia's Yutrepia infringes two foundational claims of United Therapeutics' '327' patent covering PH-ILD treatment methods and dry-powder delivery features. The decision weakens Yutrepia's near-term commercial outlook and reinforces legal protection around United Therapeutics' Tyvaso franchise. Liquidia plans to appeal and petition the FDA to remove the PH-ILD indication from Yutrepia's label, with final judgment expected within a week.
Impact level
● Medium
Affected assets
NCSKHL2USD/USDT-1.28%
AI Insight · NCSKHL2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
A US federal court in Delaware ruled that Liquidia’s lung drug Yutrepia infringed two foundational claims of United Therapeutics’ '327 patent, sending Liquidia shares down nearly 50% on Wednesday. United Therapeutics shares rose 12.3% the same day. Liquidia said it disagrees with the decision, will pursue appellate options and plans to ask the FDA to remove the PH-ILD indication from Yutrepia’s label. A final judgment is expected within about a week.
